Amicus Therapeutics, Inc. (FOLD)
| Market Cap | 2.10B |
| Revenue (ttm) | 317.83M |
| Net Income (ttm) | -270.06M |
| Shares Out | 280.16M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 653,087 |
| Open | 7.46 |
| Previous Close | 7.74 |
| Day's Range | 7.13 - 7.63 |
| 52-Week Range | 5.91 - 12.63 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | 14.62 (+95.2%) |
| Earnings Date | May 9, 2022 |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate t...
Financial Performance
In 2021, FOLD's revenue was $305.51 million, an increase of 17.11% compared to the previous year's $260.89 million. Losses were -$250.46 million, -9.53% less than in 2020.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is 14.62, which is an increase of 95.19% from the latest price.
News
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorP...
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biolo...
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M
Amicus Therapeutics Announces First Quarter 2022 Financial Results
1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M
Why Amicus (FOLD) Might Surprise This Earnings Season
Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bears are Losing Control Over Amicus Therapeutics (FOLD), Here's Why It's a 'Buy' Now
Amicus Therapeutics (FOLD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement am...
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in...
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m...
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent P...
Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expire in 2038 Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expir...
Amicus Therapeutics Among Small Biotechs Cutting Back
Amicus Therapeutics Inc. ( FOLD , Financial) is the poster child for the malaise affecting small biotechs, especially those working on gene and cell therapy. Owners of the stock are hoping the company's...
Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
Amicus Therapeutics Inc (NASDAQ: FOLD) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up to 3...
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA...
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be ...
Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42n...
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
Galafold ® Revenue Growth of 17% YoY to $306M in 2021
Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market conditions" sinking the planned merger with ARYA Sc...
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022
PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 at 8...
Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022
PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare di...
Amicus Therapeutics (FOLD) Stock Jumps 6.4%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
Full-Year 2021 Galafold ® Revenue of ~$306M, Representing 17% YoY Growth